Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06632496 · ClinicalTrials.gov registry record
BD Prevue(TM) II Peripheral Vascular Access System With Cue(TM) Needle Tracking Technology Clinical Study
A clinical trial of BD Prevue II for Peripheral Intravenous Catheter Placement, sponsored by Becton, Dickinson and Company.
- Completed
- Registry status
- 156
- Enrollment target
- 2
- Study locations
NCT06632496: Completed study of BD Prevue II for Peripheral Intravenous Catheter Placement, sponsored by Becton, Dickinson and Company.
NCT06632496 is a study of BD Prevue II for Peripheral Intravenous Catheter Placement that has completed, run by Becton, Dickinson and Company. The registered enrollment target is 156 participants. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06632496, a study of BD Prevue II for Peripheral Intravenous Catheter Placement, has completed, sponsored by Becton, Dickinson and Company.
- COMPLETED
- Registry status
- 156 participants
- Enrollment target
- 2
- Study locations
Study Summary
This post-market study is being conducted to generate safety and performance data on the BD Prevue(TM) II Peripheral Vascular Access System with Cue(TM) Needle Tracking Technology. The data will be utilized to support regional registrations (for example, EU MDR), and document any unforeseen residual risks.
Primary Outcome
The PrevueTM II system is able to visualize the target vasculature (\>=70% with a 95% confidence interval)
Conditions Studied
Interventions
- DEVICE BD Prevue(TM) II
Study Locations (2)
New York
- Brookdale University Hospital & Medical Center - Brooklyn
Pennsylvania
- Allegheny Health Network Research Institute - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2025-03-28 |
| Est. Completion | 2025-09-23 |
What the finished NCT06632496 record still lists
NCT06632496 is an observational study that tracks outcomes without assigning an intervention. The registered 156 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with BD Prevue II for Peripheral Intravenous Catheter Placement appearing as the primary indexed condition, and to 1 intervention - of which BD Prevue(TM) II is the first listed.
NCT06632496 reports a single indexed study location in New York, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06632496 about?
NCT06632496 is a clinical study titled "BD Prevue(TM) II Peripheral Vascular Access System With Cue(TM) Needle Tracking Technology Clinical Study". This post-market study is being conducted to generate safety and performance data on the BD Prevue(TM) II Peripheral Vascular Access System with Cue(TM) Needle Tracking Technology. The data will be utilized to support regional registrations (for example, EU MDR), and document any unforeseen residual...
What is the current status of trial NCT06632496?
This trial is currently completed. The enrollment target is 156 participants. The study started on 2025-03-28. Estimated completion is 2025-09-23.
What conditions does trial NCT06632496 study?
This clinical trial studies the following conditions: BD Prevue II for Peripheral Intravenous Catheter Placement.
What interventions are being tested in trial NCT06632496?
The interventions under investigation include: BD Prevue(TM) II (DEVICE).
Who is sponsoring clinical trial NCT06632496?
This trial is sponsored by Becton, Dickinson and Company, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06632496 being conducted?
This trial has 2 study locations across New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03082755 · 156 participants · Phase 4
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
- NCT04047628 · 156 participants · Phase 3
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
- NCT04166877 · 156 participants · Phase 4
Magnesium Infusion for Pain Management in Critically Ill Trauma Patients
- NCT04533464 · 156 participants · Phase 2
MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI